Literature DB >> 25869581

Development and validation of a predictive risk model for all-cause mortality in type 2 diabetes.

Tom E Robinson1, C Raina Elley2, Tim Kenealy2, Paul L Drury3.   

Abstract

AIMS: Type 2 diabetes is common and is associated with an approximate 80% increase in the rate of mortality. Management decisions may be assisted by an estimate of the patient's absolute risk of adverse outcomes, including death. This study aimed to derive a predictive risk model for all-cause mortality in type 2 diabetes.
METHODS: We used primary care data from a large national multi-ethnic cohort of patients with type 2 diabetes in New Zealand and linked mortality records to develop a predictive risk model for 5-year risk of mortality. We then validated this model using information from a separate cohort of patients with type 2 diabetes.
RESULTS: 26,864 people were included in the development cohort with a median follow up time of 9.1 years. We developed three models initially using demographic information and then progressively more clinical detail. The final model, which also included markers of renal disease, proved to give best prediction of all-cause mortality with a C-statistic of 0.80 in the development cohort and 0.79 in the validation cohort (7610 people) and was well calibrated. Ethnicity was a major factor with hazard ratios of 1.37 for indigenous Maori, 0.41 for East Asian and 0.55 for Indo Asian compared with European (P<0.001).
CONCLUSIONS: We have developed a model using information usually available in primary care that provides good assessment of patient's risk of death. Results are similar to models previously published from smaller cohorts in other countries and apply to a wider range of patient ethnic groups.
Copyright © 2015. Published by Elsevier Ireland Ltd.

Entities:  

Keywords:  Diabetes mellitus type 2; Mortality; New Zealand; Risk assessment; Risk factors; Survival analysis

Mesh:

Year:  2015        PMID: 25869581     DOI: 10.1016/j.diabres.2015.02.015

Source DB:  PubMed          Journal:  Diabetes Res Clin Pract        ISSN: 0168-8227            Impact factor:   5.602


  5 in total

1.  Estimation of Mortality Risk in Type 2 Diabetic Patients (ENFORCE): An Inexpensive and Parsimonious Prediction Model.

Authors:  Massimiliano Copetti; Hetal Shah; Andrea Fontana; Maria Giovanna Scarale; Claudia Menzaghi; Salvatore De Cosmo; Monia Garofolo; Maria Rosaria Sorrentino; Olga Lamacchia; Giuseppe Penno; Alessandro Doria; Vincenzo Trischitta
Journal:  J Clin Endocrinol Metab       Date:  2019-10-01       Impact factor: 5.958

2.  Excess of all-cause mortality after a fracture in type 2 diabetic patients: a population-based cohort study.

Authors:  D Martinez-Laguna; X Nogues; B Abrahamsen; C Reyes; C Carbonell-Abella; A Diez-Perez; D Prieto-Alhambra
Journal:  Osteoporos Int       Date:  2017-07-25       Impact factor: 4.507

3.  Large-scale evidence generation and evaluation across a network of databases for type 2 diabetes mellitus (LEGEND-T2DM): a protocol for a series of multinational, real-world comparative cardiovascular effectiveness and safety studies.

Authors:  Rohan Khera; Martijn J Schuemie; Yuan Lu; Anna Ostropolets; RuiJun Chen; George Hripcsak; Patrick B Ryan; Harlan M Krumholz; Marc A Suchard
Journal:  BMJ Open       Date:  2022-06-09       Impact factor: 3.006

4.  Predicting 10-Year Risk of End-Organ Complications of Type 2 Diabetes With and Without Metabolic Surgery: A Machine Learning Approach.

Authors:  Ali Aminian; Alexander Zajichek; David E Arterburn; Kathy E Wolski; Stacy A Brethauer; Philip R Schauer; Steven E Nissen; Michael W Kattan
Journal:  Diabetes Care       Date:  2020-02-06       Impact factor: 17.152

5.  Serum resistin is causally related to mortality risk in patients with type 2 diabetes: preliminary evidences from genetic data.

Authors:  Andrea Fontana; Lorena Ortega Moreno; Olga Lamacchia; Concetta De Bonis; Lucia Salvemini; Salvatore De Cosmo; Mauro Cignarelli; Massimiliano Copetti; Vincenzo Trischitta; Claudia Menzaghi
Journal:  Sci Rep       Date:  2017-03-03       Impact factor: 4.379

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.